US › Healthcare

Enlivex Therapeutics Ltd (ENLV)

US · Healthcare · Biotechnology

$0.73-10.36%

Last close · 2026-09-17

Latest quarter · ended 2025-12-31

Revenue

Net profit

$1.24B

EPS

$-1.20

EPS estimate

$-0.31

EPS came in at -1.20 against a street estimate of -0.31 — a miss of 287.1%.

Key statistics

Market cap

$12.7M

P/E

0.0

Forward P/E

0.0

P/B

0.01

Book value

$122.27

EPS (TTM)

$342.67

52-week high

$19.80

52-week low

$0.64

50-day MA

$2.64

200-day MA

$10.79

Beta

1.42

Analyst view

Analysts rate Enlivex Therapeutics Ltd a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $80.00.

Shareholding

Insiders

78.36%

Institutions

1.62%

Largest institutional holders

Fund	Stake
Diametric Capital, LP	0.57%
ARK Investment Management LLC	0.24%
Springbok Capital Management, LLC	0.09%
Two Sigma Investments LLC	0.07%
UBS Group AG	0.05%
Bank of America Corp	0.05%
Renaissance Technologies Corp	0.05%
JPMorgan Chase & Co	0.05%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Enlivex Therapeutics Ltd — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.